Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Carmelo Juárez-Castelló"'
Publikováno v:
Gaceta Sanitaria, Vol 22, Iss 6, Pp 593-595 (2008)
Externí odkaz:
https://doaj.org/article/c1aa055459fa463d91c41fcbb7784cb0
Publikováno v:
The European Journal of Health Economics. 24:485-487
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c373ffd9273301557271aa937ca07b4e
https://doi.org/10.1007/s10198-023-01580-z
https://doi.org/10.1007/s10198-023-01580-z
Autor:
Maarten J. Postma, Paula Rojas García, Simon van der Pol, Fernando Antoñanzas, Roberto Rodríguez-Ibeas, Marino González, Carmelo Juárez-Castelló, Antoinette D I van Asselt
Publikováno v:
Antibiotics, Vol 10, Iss 55, p 55 (2021)
Antibiotics
Antibiotics
Background: The most recommended treatment for a Helicobacter pylori infection is high doses of combined antibiotics. The objective of this article is to perform a systematic review of the economic evaluation studies applied to assess the efficiency
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa94090e467bc5a54dd02244ad3db349
https://hdl.handle.net/11370/d4735153-5bda-4bfb-ad91-3afc020496cf
https://hdl.handle.net/11370/d4735153-5bda-4bfb-ad91-3afc020496cf
Publikováno v:
PharmacoEconomics. 37(12)
The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders’ perceptions. We conducted a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e256801e883384a4335cbfd365061a25
https://pubmed.ncbi.nlm.nih.gov/31535280
https://pubmed.ncbi.nlm.nih.gov/31535280
Publikováno v:
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
Health Economics Review
Health Economics Review, Vol 9, Iss 1, Pp 1-10 (2019)
instname
Health Economics Review
Health Economics Review, Vol 9, Iss 1, Pp 1-10 (2019)
Background Currently, personalised medicine is becoming more frequently used and many drug companies are including this strategy to gain market access for very specialized therapies. In this article, in order to understand the relationships between t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7edd951466ed26b38c0fc39792e72ed4
https://investigacion.unirioja.es/documentos/5de5a2b129995277fde7ce59
https://investigacion.unirioja.es/documentos/5de5a2b129995277fde7ce59
Publikováno v:
Studies of Applied Economics. 31:359
In this article, we model the relationship between a health authority and a pharmaceutical firm when the real efficacy of the drug manufactured by the firm is uncertain. The ex-ante information on the efficacy of the new drug is provided by the outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebcbf565920aecae270fc9ec0abdc61
https://doi.org/10.25115/eea.v31i2.3331
https://doi.org/10.25115/eea.v31i2.3331
Publikováno v:
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
RIUR: Repositorio Institucional de la Universidad de La Rioja
Universidad de La Rioja (UR)
instname
RIUR: Repositorio Institucional de la Universidad de La Rioja
Universidad de La Rioja (UR)
In this article, we model the behavior of a pharmaceutical firm that has marketing authorization for a new therapy believed to be a candidate for personalized use in a subset of patients, but that lacks information as to why a response is seen only i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122d5d3c2ba3b4f9f71310b279647c91
https://investigacion.unirioja.es/documentos/5bbc6821b750603269e80323
https://investigacion.unirioja.es/documentos/5bbc6821b750603269e80323
Publikováno v:
The European journal of health economics : HEPAC : health economics in prevention and care. 19(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fbe1ecbcea863f1c2c0bc7b904b33e5
https://pubmed.ncbi.nlm.nih.gov/29188395
https://pubmed.ncbi.nlm.nih.gov/29188395
Publikováno v:
RIUR: Repositorio Institucional de la Universidad de La Rioja
Universidad de La Rioja (UR)
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
Universidad de La Rioja (UR)
RIUR. Repositorio Institucional de la Universidad de La Rioja
instname
In this paper we carry out a vertical differentiation duopoly model applied to pharmaceutical markets to analyze how endogenous and exogenous generic reference pricing influence competition between generic and branded drugs producers. Unlike the lite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12b1b1b5e50c7d8e0dd92fd27a92ea2
https://investigacion.unirioja.es/documentos/5bbc693bb750603269e81794
https://investigacion.unirioja.es/documentos/5bbc693bb750603269e81794
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 14:617-626
This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized stati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecefbc5128b9b1b13cbe37ed79c698fe
https://doi.org/10.1586/14737167.2014.927315
https://doi.org/10.1586/14737167.2014.927315